13F Holdings
中文EN

IMVT Immunovant, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1764013 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-9.5%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-86.5%
ROA-75.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets13.7%
Debt / equity0.00x
Current ratio7.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-17.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue—————
R&D expense$456.66M$360.92M$212.93M$160.26M$101.81M
SG&A expense$76.24M$77.23M$57.28M$48.02M$54.23M
Pretax income-$505.39M-$412.95M-$258.77M-$210.95M-$156.81M
Income tax$215,000$891,000$567,000$9,000-$84,000
Net income-$505.61M-$413.84M-$259.34M-$210.96M-$156.73M
EPS (basic)-2.77-2.73-1.88-1.71-1.43
EPS (diluted)-2.77-2.73-1.88-1.71-1.43
Weighted avg. shares (diluted)182.42M151.57M138.10M123.08M109.68M
Banking
Net interest income——$24.95M$7.58M$0
Balance sheet
Cash & equivalents$902.11M$713.97M$635.37M$376.53M$493.82M
Receivables$1.13M$2.08M$5.34M$700,000$12.23M
Current assets$948.82M$767.66M$665.77M$404.33M$512.93M
PP&E, net$443,000$844,000$462,000$333,000$330,000
Total assets$957.01M$776.22M$666.37M$405.84M$515.56M
Current liabilities$104.42M$68.78M$48.61M$43.30M$44.52M
Total liabilities$104.42M$68.78M$48.61M$43.34M$45.74M
Shareholders' equity$852.59M$707.45M$617.76M$362.49M$469.82M
Shares outstanding203.94M170.11M145.58M130.33M116.48M
Cash flow statement
Operating cash flow-$407.31M-$375.87M-$214.23M-$188.19M-$106.11M
Capital expenditure$8,000$759,000$360,000$197,000$254,000
Free cash flow-$407.32M-$376.63M-$214.59M-$188.39M-$106.37M
Investing cash flow-$8,000-$759,000-$360,000-$197,000-$254,000
Financing cash flow$595.76M$454.49M$472.43M$70.89M$200.13M
Depreciation & amortization$409,000$377,000$231,000$193,000$126,000
Stock-based compensation$55.72M$49.49M$41.12M$32.30M$34.24M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.